FGFR3 and carcinoma: Furthermore, certain molecular markers have been evaluated such as point mutations in the FGFR3 gene, which were detected in 85% of PUNLMP tumors and in 88% of low-grade carcinomas [29], and in our data, Fig. 4 shows a significant overlap between PULNMP and LGPUC in predicting tumor recurrence after complete TUR.